Personalized high-dose aflibercept for a type of wet AMD
Treatments studied
Part of Eyes & vision clinical trials.
This trial tests a higher dose of aflibercept (a drug that blocks abnormal blood vessel growth) for people with a specific form of wet age-related macular degeneration called polypoidal choroidal vasculopathy. The goal is to see if a personalized treatment plan with this stronger dose is safe and effective for those who have not been treated before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 19 years or older.
- You need to have active polypoidal lesions in the macula with signs of fluid or bleeding, as confirmed by special eye tests.
- Your vision in the study eye must be between 20/30 and 20/400 on an eye chart.
- You must not have had any previous eye treatments for this condition, such as anti-VEGF injections, laser, or surgery other than cataract surgery.
- You cannot have had a stroke or heart attack in the last 6 months.
- You must not have received any systemic anti-VEGF therapy at any time.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized treatment plan using an investigational drug called faricimab for people who have a specific type of wet age-related macular degeneration known as polypoidal choroidal vasculopathy. The goal is to see if adjusting the time between injections based on your individual needs can safely dry up fluid in the retina and improve vision.
This study tests a new higher-dose version of an eye injection called aflibercept (Eylea) for people with a specific type of wet age-related macular degeneration called polypoidal choroidal vasculopathy (PCV). The goal is to see if this treatment is effective, long-lasting, and safe, and it may help improve or preserve your vision.
This study tests a higher dose of a drug called aflibercept, given as eye injections, for people with untreated wet age-related macular degeneration (AMD). The goal is to see if it can improve vision and how often it needs to be given.
This study tests whether switching to a higher dose of aflibercept (Eylea) is safe and effective for people with wet age-related macular degeneration who are already receiving standard-dose aflibercept. The goal is to see if the higher dose can better control the disease and possibly extend the time between injections.
This trial tests a high-dose version of the drug aflibercept (given as an eye injection) for people with diabetic macular edema who have previously had a vitrectomy surgery. The goal is to see if this higher dose can help reduce swelling and improve vision.
This study follows patients receiving aflibercept 8 mg injections in the eye to treat wet age-related macular degeneration (nAMD), a condition that blurs central vision. The goal is to understand how well this treatment works and its safety in routine medical practice.
Hear when a new Polypoidal Choroidal Vasculopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.